代谢相关性脂肪性肝病流行现状

doi:10.3969/j.issn.1672-5069.2023.06.003

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (6): 777-780.doi: 10.3969/j.issn.1672-5069.2023.06.003

代谢相关性脂肪性肝病流行现状

施漪雯, 范建高

200092 上海市上海交通大学医学院附属新华医院消化内科

收稿日期:2023-10-01 出版日期:2023-11-10 发布日期:2023-11-20
通讯作者: 范建高,Email:fattyliver2004@126.com
作者简介:施漪雯,女,33岁,医学博士,主治医师,Email:yiwenshi90@163.com

Epidemiologic status of metabolic dysfunction-associated fatty liver diseases

Shi Yiwen, Fan Jiangao

Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai 200092, China

Received:2023-10-01 Online:2023-11-10 Published:2023-11-20

摘要/Abstract

Key words: Metabolic dysfunction-associated fatty liver diseases, Obesity, Diabetes, Metabolic syndrome, Prevalence, Incidence

施漪雯, 范建高. 代谢相关性脂肪性肝病流行现状[J]. 实用肝脏病杂志, 2023, 26(6): 777-780.

Shi Yiwen, Fan Jiangao. Epidemiologic status of metabolic dysfunction-associated fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(6): 777-780.

[1] 杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查. 实用肝脏病杂志,2022,25(2):153-156.
[2] 苏佩华. 慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌. 实用肝脏病杂志, 2023,26(3):445-448.
[3] Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty Liver disease. Gastroenterology, 2020,158(7):1999-2014,e1991.
[4] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020,73(1):202-209.
[5] Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol, 2023[ahead of print].
[6] Yip TC, Fan JG, Wong VW. China’s fatty liver crisis: A looming public health emergency. Gastroenterology, 2023,165(4):825-827.
[7] Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2022,7(9):851-861.
[8] Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 2023,77(4):1335-1347.
[9] Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2023,8(1):20-30.
[10] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol, 2019,71(4):793-801.
[11] Ye Q, Zou BY, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2020,5(8):739-752.
[12] En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut, 2023[ahead of print].
[13] Le MH, Le DM, Baez TC, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol, 2023,79(2):287-295.
[14] Zhou JH, Zhou F, Wang WX, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology, 2020,71(5):1851-1864.
[15] Man S, Deng YH, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China. Gastroenterology, 2023,165(4):1025-1040.
[16] 胡灵溪, 安薪宇, 李妹, 等. 超声衰减参数诊断体检人群脂肪肝临床应用价值分析. 实用肝脏病杂志,2023,26(4):488-491.
[17] 范建高, 李小英. NAFLD更名MAFLD、MASLD:背景、异同、对策. 中华肝脏病杂志, 2023,31(8):789-792.
[18] Zeng J, Qin L, Jin Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. Hepatobiliary Pancreat Dis Int, 2022,21(2):154-161.
[19] Song SJ, Lai JC, Wong GL, et al. Can we use old NAFLD data under the new MASLD definition? J Hepatol, 2023[ahead of print].
[20] Perazzo H, Pacheco AG, Griep RH, et al. Changing from NAFLD trough MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort. J Hepatol, 2023[ahead of print].
[21] Zou ZY, Zeng J, Ren TY, et al. The burden and sexual dimorphism with nonalcoholic fatty liver disease in Asian children: A systematic review and meta‐analysis. Liver Int, 2021,42(9):1969-1980.
[22] Xing YF, Fan JG, Wang HJ, et al. Comparison of MAFLD and NAFLD characteristics in children. Children, 2023,10(3):560.
[23] Zeng J, Jin Q, Yang J, et al. Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort. Hepatol Int, 2023[ahead of print].
[24] Zeng J, Shen F, Zou ZY, et al. Association of maternal obesity and gestational diabetes mellitus with overweight/obesity and fatty liver risk in offspring. World J Gastroenterol, 2022,28(16):1681-1691.
[25] 顾棨, 芮法娟, 倪文婧, 等. 非酒精性脂肪性肝病的规范化管理. 实用肝脏病杂志, 2023,26(4):457-460.
[26] 张淮, 郑明华. MAFLD高危人群的筛查和分层管理. 实用肝脏病杂志, 2023,26(4):463-466.

代谢相关性脂肪性肝病流行现状

Epidemiologic status of metabolic dysfunction-associated fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.
[2]	丁晓洁, 张永明, 宋海燕, 王文平, 宋洁, 撒小军, 邹永红. 2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 815-818.
[3]	宁月季, 成家飞, 钱佶, 朱瑞农. 2型糖尿病与非2型糖尿病患者发生细菌性肝脓肿临床特征分析^*[J]. 实用肝脏病杂志, 2023, 26(5): 730-733.
[4]	张淮, 郑明华. MAFLD高危人群的筛查和分层管理^*[J]. 实用肝脏病杂志, 2023, 26(4): 463-465.
[5]	尹会芬, 于红艳, 刘志平. 非酒精性脂肪性肝病合并2型糖尿病患者血清瘦素、视黄醇结合蛋白4和胆碱酯酶水平变化及其临床意义研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 500-503.
[6]	王云云, 吴万锋, 李黎. 直接抗病毒药物治疗基因1b型慢性丙型肝炎合并2型糖尿病患者疗效及对血糖控制的影响^*[J]. 实用肝脏病杂志, 2023, 26(3): 344-347.
[7]	赵玲玲, 王贝贝, 姚勇利, 郑有花, 李亚楠. T2DM合并非酒精性脂肪性肝病伴进展性肝纤维化患者血清抵抗素和TyG指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(3): 356-359.
[8]	张威, 陈国林, 王航, 余良, 孔祥璐. 合并不同基础疾病的细菌性肝脓肿患者临床特征分析[J]. 实用肝脏病杂志, 2023, 26(3): 424-427.
[9]	李潇萌, 吴少玉, 王媛媛. 非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 202-205.
[10]	孙峥, 王笑烨, 袁景, 梁丽. 达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 796-799.
[11]	蔡勇, 李璟, 欧琴. 2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 800-803.
[12]	孙凌, 杭玮, 邓国忠. 二甲双胍联合吡格列酮治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 804-807.
[13]	王玉梅, 袁向东, 刘玉玲, 赵子瑜. 提示肥胖症儿童/青少年存在非酒精性脂肪性肝炎的指标分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 808-811.
[14]	郑希彦, 杜飞, 林志群, 李瑞曦, 周正, 张广权, 周红, 何方平, 史宪杰. 肝细胞癌进展:代谢综合征相关危险因素研究[J]. 实用肝脏病杂志, 2022, 25(6): 877-880.
[15]	米朦, 卢秉久, 王学良, 王晓彤, 郑佳连. 代谢相关性脂肪性肝病患者血脂分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 653-656.